Session » Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA

Date: Friday, November 6, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 0144

Age, Income, Education, and Health Conditions Are Associated with Patient Empowerment Among US Adults with Arthritis, but Race and Geography Are Not

9:00AM-11:00AM: Abstract Number: 0138

Alignment and Discordances in Treatment Perceptions and Shared Decision-Making Among RA Patients and Rheumatology Care Teams

9:00AM-11:00AM: Abstract Number: 0155

Changes in Patient-Reported Outcome (PRO) Scores for Nausea and Fatigue Following Weekly Methotrexate Dose in a Real-World Sample of RA and PsA Patients in the ArthritisPower Registry

9:00AM-11:00AM: Abstract Number: 0163

Cost of Non-Persistence in the Treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors of Inflammatory Arthritis: A Propensity Score Matching Approach

9:00AM-11:00AM: Abstract Number: 0153

Counseling on Safe Driving Strategies in Patients with Osteoarthritis and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0157

Early Arthritis Global Assesment: What Differences Exist Between Patients and Physicians?

9:00AM-11:00AM: Abstract Number: 0142

Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs: Results from the FINCH 2 Study

9:00AM-11:00AM: Abstract Number: 0141

Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results from FINCH-1 Study

9:00AM-11:00AM: Abstract Number: 0143

Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis Who Are Methotrexate-naïve: Results from the FINCH-3 Study

9:00AM-11:00AM: Abstract Number: 0136

Filgotinib Significantly Improved Patient-reported Health-related Quality of Life for Patients with Active Rheumatoid Arthritis: A Post Hoc Analysis of SF-36 and HAQ-DI from Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 0149

How Stable Are Medication Necessity Beliefs and Safety Concerns in the First Year of RA?

9:00AM-11:00AM: Abstract Number: 0162

Identifying Sleep Problems in Systemic Juvenile Idiopathic Arthritis (SJIA) Patients with Patient-reported Outcomes (PRO) Questionnaires

9:00AM-11:00AM: Abstract Number: 0168

Impact of Adalimumab (Humira) Therapy on Ocular Inflammation, Selected Health Care Resource Utilization, and Patient-Reported Outcomes in Patients with Active Non-infectious Intermediate, Posterior, or Panuveitis in Routine Clinical Practice

9:00AM-11:00AM: Abstract Number: 0140

Meaningful Within-Patient Change in WOMAC Domains in Patients with Moderate-To- Severe Osteoarthritis

9:00AM-11:00AM: Abstract Number: 0151

More Than Half of Newly Diagnosed RA Patients Are Not Convinced of the Necessity of RA Medicines: Associations with RA Characteristics, Symptoms, and Function in the Canadian Early Arthritis Cohort (CATCH)

9:00AM-11:00AM: Abstract Number: 0159

Patient-Reported Data Show the Impact of Time to Diagnosis in RA

9:00AM-11:00AM: Abstract Number: 0169

Patient-Reported Outcomes Differentiate Between Remission and Low Disease Activity in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0146

Patients’ Perceptions and Expectations Towards the Role of Rheumatologists in the Recommendations of Physical Activity’s Practice – A Cross-sectional Study Involving 308 Patients Living with Rheumatoid Arthritis in France

9:00AM-11:00AM: Abstract Number: 0148

Perspectives on Treatment Burden for Methotrexate and TNF-inhibitors Among Psoriatic Arthritis and Rheumatoid Arthritis Patients: A Qualitative Study

9:00AM-11:00AM: Abstract Number: 0166

Prevalence and Impact of Unacceptable Symptom State Among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation’s 2019 Annual Survey

9:00AM-11:00AM: Abstract Number: 0137

PROMIS-29 Scores Are Significantly Higher in Patients with Rheumatoid Arthritis Who Meet Criteria for Co-morbid Fibromyalgia (FM) Than in Those with Rheumatoid Arthritis and No FM

9:00AM-11:00AM: Abstract Number: 0158

Relationships Between Disease Patterns in RA and Rheumatology Treatment

9:00AM-11:00AM: Abstract Number: 0167

Rheumatoid Arthritis Patient Phenotypes from a Digital Health Coaching Engagement Program

9:00AM-11:00AM: Abstract Number: 0139

Routine Assessment of Patient Index Data (RAPID) 3 as a Predictor of Weight Reduction in Rheumatology Patients Undergoing Bariatric Surgery

9:00AM-11:00AM: Abstract Number: 0134

The Impact of Exercise on Sleep in People with Rheumatoid Arthritis: A Pilot Randomised Controlled Trial

9:00AM-11:00AM: Abstract Number: 0147

The Interpretation of Patient-reported Outcomes in Rheumatoid Arthritis: Do Clinical Trials Adequately Evaluate Meaningful Improvements for Patients?

9:00AM-11:00AM: Abstract Number: 0150

The Preparation Experience for Total Knee Arthroplasty of Patients with Osteoarthritis: A Cross-Sectional Survey

9:00AM-11:00AM: Abstract Number: 0156

The Role of Biological Treatment in the Health-Related Quality of Life of Ankylosing Spondylitis Patients’ Assessment – Meta-Analysis

9:00AM-11:00AM: Abstract Number: 0145

Treat-to-Target in Rheumatoid Arthritis: Rates of Treatment Changes in Patients Engaged with Care Management Services Compared to Historically Reported National Registry Based Estimates

9:00AM-11:00AM: Abstract Number: 0154

Treatment Decision Making Among Axial Spondyloarthritis Patients: Real-World Data from the ArthritisPower Registry

9:00AM-11:00AM: Abstract Number: 0135

Understanding the Rheumatologist-Patient Relationship in Treating Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0160

Use of PROMIS29 Across Inflammatory Arthritis: Score Distributions and Impact of Contextual Factors

9:00AM-11:00AM: Abstract Number: 0170

Utilizing Design Thinking to Develop a Decision Aid for Patients with Psoriasis and Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0161

Validation of Patient-reported Outcomes (PRO) Lung Questionnaires for Systemic Juvenile Idiopathic Arthritis (SJIA) Patients at Risk for Lung Disease

9:00AM-11:00AM: Abstract Number: 0152

Veterans with RA and Gout Identify Their Goals and How They Can Work with Clinicians to Achieve Their Goals

9:00AM-11:00AM: Abstract Number: 0164

What’s in a Name? Patient and Family Perspectives on the Naming of Systemic Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 0165

Work Disability and Predictors of Poor Work Outcome in Patients with Axial Spondyloarthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].